148.70

0.24% 0.36

After Hours: 148.70

Glaukos Corp (GKOS)

Overview News Price History Option Chain Financials Discussions Forecast

Glaukos Corp stock is traded at $148.70, with a volume of 712.92K. It is up +0.24% in the last 24 hours and up +18.96% over the past month. Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Previous Close:

$148.34

Open:

$150

24h Volume:

712.92K

Relative Volume:

0.75

Market Cap:

$8.73B

Revenue:

$551.35M

Net Income/Loss:

$-189.33M

P/E Ratio:

-45.18

EPS:

-3.2916

Net Cash Flow:

$-35.09M

1W Performance:

+4.58%

1M Performance:

+18.96%

6M Performance:

+32.44%

1Y Performance:

+43.67%

1-Day Range:

$146.69

$150.26

1-Week Range:

$136.18

$150.26

52-Week Range:

$73.16

$150.26

Glaukos Corp Stock (GKOS) Company Profile

Name

Glaukos Corp

Sector

Healthcare (1100)

Industry

Medical Devices (142)

Phone

949-367-9600

Address

1 GLAUKOS WAY, ALISO VIEJO, CA

Employee

1,094

Twitter

@GlaukosCorp

Next Earnings Date

2026-07-29

Latest SEC Filings

GKOS's Discussions on Twitter

Compare GKOS vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GKOS Glaukos Corp	148.70	8.21B	551.35M	-189.33M	-35.09M	-3.2916
ABT Abbott Laboratories	95.63	158.05B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	324.73	120.70B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	83.06	100.14B	36.36B	4.84B	5.43B	3.7212
BSX Boston Scientific Corp	44.60	63.44B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	95.18	52.09B	6.30B	1.07B	1.09B	1.8406

Glaukos Corp Stock (GKOS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-27-25	Upgrade	Wells Fargo	Equal Weight → Overweight
Oct-01-25	Initiated	Goldman	Buy
May-01-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Feb-19-25	Upgrade	Mizuho	Neutral → Outperform
Dec-11-24	Upgrade	Citigroup	Neutral → Buy
Dec-06-24	Initiated	UBS	Buy
Dec-02-24	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Jul-10-24	Downgrade	Citigroup	Buy → Neutral
May-06-24	Upgrade	Jefferies	Hold → Buy
Dec-21-23	Upgrade	JP Morgan	Neutral → Overweight
Dec-04-23	Initiated	Morgan Stanley	Equal-Weight
Nov-28-23	Initiated	Truist	Buy
Nov-08-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Jun-07-23	Upgrade	Piper Sandler	Neutral → Overweight
Dec-22-22	Initiated	Mizuho	Neutral
Dec-19-22	Upgrade	JP Morgan	Underweight → Neutral
Dec-12-22	Upgrade	Citigroup	Neutral → Buy
Oct-14-22	Resumed	Stephens	Overweight
Oct-04-22	Initiated	Needham	Buy
Jul-12-22	Upgrade	Stifel	Hold → Buy
Feb-03-22	Upgrade	William Blair	Mkt Perform → Outperform
Jan-19-22	Upgrade	Wells Fargo	Underweight → Equal Weight
Jan-18-22	Upgrade	BTIG Research	Neutral → Buy
Nov-03-21	Upgrade	Stephens	Equal-Weight → Overweight
Jul-26-21	Downgrade	Stephens	Overweight → Equal-Weight
Jul-20-21	Downgrade	Wells Fargo	Equal Weight → Underweight
Jul-14-21	Downgrade	Oppenheimer	Outperform → Perform
Jul-14-21	Downgrade	William Blair	Outperform → Mkt Perform
Apr-08-21	Upgrade	Oppenheimer	Perform → Outperform
Jan-29-21	Downgrade	Piper Sandler	Overweight → Neutral
Dec-16-20	Upgrade	Citigroup	Sell → Neutral
Dec-09-20	Initiated	Oppenheimer	Perform
Nov-17-20	Upgrade	Wells Fargo	Underweight → Equal Weight
Oct-08-20	Downgrade	JP Morgan	Neutral → Underweight
Jun-15-20	Initiated	Jefferies	Hold
Mar-05-20	Initiated	Citigroup	Sell
Feb-28-20	Downgrade	JP Morgan	Overweight → Neutral
Jan-06-20	Upgrade	Berenberg	Hold → Buy
Dec-12-19	Downgrade	Wells Fargo	Outperform → Underperform
Sep-30-19	Downgrade	BofA/Merrill	Buy → Underperform
Mar-08-19	Initiated	BTIG Research	Neutral
Aug-30-18	Initiated	Berenberg	Hold
Aug-29-18	Upgrade	JP Morgan	Neutral → Overweight
Aug-03-18	Reiterated	Stifel	Hold
Jun-21-18	Downgrade	JP Morgan	Overweight → Neutral
Apr-13-18	Downgrade	Stifel	Buy → Hold
Mar-01-18	Reiterated	Cantor Fitzgerald	Buy
Mar-02-17	Reiterated	Cantor Fitzgerald	Overweight
Jan-06-17	Upgrade	Stifel	Hold → Buy
Oct-27-16	Initiated	Wells Fargo	Outperform

View All

Glaukos Corp Stock (GKOS) Latest News

Jul 01, 2026

Form 144 GLAUKOS Corp For: 1 July - Investing.com UK

Jul 01, 2026

Form 144 GLAUKOS Corp For: 1 July By Investing.com - Investing.com Canada

Jul 01, 2026

GKOS (GKOS) insider sells 3,630 shares total across April and June 2026 - Stock Titan

Jul 01, 2026

GKOS Reiterated by Piper Sandler -- Price Target Maintained at $165 - GuruFocus

Jul 01, 2026

Piper Sandler reiterates Glaukos stock rating on iDose headwinds By Investing.com - Investing.com Canada

Jul 01, 2026

Jun 29, 2026

Form 4 Glaukos Corp For: 29 June By Investing.com - Investing.com South Africa

Jun 29, 2026

Glaukos (NYSE: GKOS) CEO updates trust holdings, uses shares for tax withholding - Stock Titan

Jun 29, 2026

Glaukos (NYSE: GKOS) president has 1,056 shares withheld for taxes - Stock Titan

Jun 29, 2026

Glaukos (GKOS) CDO reports 483-share tax withholding, holds 88,350 shares - Stock Titan

Jun 29, 2026

Jun 27, 2026

Goldman Sachs Small Cap Equity Insights Fund's Glaukos Corp(GKOS) Holding History - GuruFocus

Jun 25, 2026

Glaukos Corp Actuals & Estimates (NYSE:GKOS) - TradingView

Jun 25, 2026

Glaukos Moves Into Demodex Blepharitis Space - Orange County Business Journal

Jun 25, 2026

Midday Stock Roundup: Glaukos Rises 4% After Phase 2 Enrollment Completed - Orange County Business Journal

Jun 25, 2026

Glaukos completes enrollment in phase 2 blepharitis study - Investing.com

Jun 25, 2026

Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis - BioSpace

Jun 25, 2026

Glaukos completes enrollment in phase 2 blepharitis study By Investing.com - Investing.com Australia

Jun 25, 2026

Glaukos (GKOS) Completes Patient Enrollment in GLK-321 Study - GuruFocus

Jun 25, 2026

Glaukos fills 275-patient trial of eyelid-disease drug candidate - Stock Titan

Jun 25, 2026